Aurora Financial JournalMoberg Pharma (Sweden) (MOB.ST)
Nasdaq Stockholm · Financial statements, TTM figures and earnings dates
In fiscal year 2024 (ended December 31, 2024), Moberg Pharma (Sweden) reported revenue of SEK 9.8M and net income of −SEK 255.1M. Annual financial statements are available for fiscal years 2021 to 2024, taken from the company's ESEF annual reports (IFRS).
Open interactive financials →Key financials
| SEK | FY2024 2024-12-31 | FY2023 2023-12-31 | FY2022 2022-12-31 | FY2021 2021-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | SEK 9.8M | SEK 0 | SEK 207.0K | SEK 0 |
| Gross profit | SEK 6.3M | SEK 0 | SEK 207.0K | SEK 0 |
| Operating income | −SEK 324.8M | −SEK 27.5M | −SEK 20.2M | −SEK 19.7M |
| Net income | −SEK 255.1M | −SEK 21.1M | −SEK 15.7M | SEK 7.5M |
| Diluted EPS | −SEK 6.74 | −SEK 1.33 | −SEK 2.07 | SEK 1.70 |
| Cash flow | ||||
| Operating cash flow | −SEK 16.5M | −SEK 33.2M | – | – |
| Balance sheet | ||||
| Cash and equivalents | SEK 293.3M | SEK 60.6M | SEK 125.5M | SEK 102.7M |
| Total assets | SEK 706.1M | SEK 634.7M | SEK 564.4M | SEK 450.9M |
| Total liabilities | SEK 19.3M | SEK 24.0M | SEK 30.8M | SEK 16.8M |
| Shareholders' equity | SEK 686.8M | SEK 610.7M | SEK 533.6M | SEK 434.1M |
TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in SEK as reported; per-share data adjusted for stock splits.
Annual reports
More on the interactive page
The full MOB.ST page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.
Open MOB.ST financials →